Tag: strum
SIGN UP FOR OUR NEWSLETTER


Quick Search

Reset

What We Should Have Learned About Prostate Cancer (PC) in the Past 10 Years: Part Three

Sun 31 Aug 2008

  by Stephen B. Strum, MD, FACP Medical Oncologist and PCRI Co-founder Ashland, OR Edited from PCRI Insights August, 2008 v 11.3 In Part I and Part II of this series, I presented an in-depth discussion of key issues relating to the chemoprevention of PC, and I discussed in depth the results of the PCPTRead More ›

What We Should Have Learned About Prostate Cancer (PC) in the Past 10 Years

Wed 27 Feb 2008

  by Stephen B. Strum, MD, FACP Medical Oncologist and PCRI Co-founder Ashland, OR Edited from PCRI Insights February, 2008 v 11.1   Overview The goal for this article is to present my views on the current status of the everyday care of the PC patient. This communication thus serves as a State of theRead More ›

What Every Doctor Who Treats Male Patients Should Know

Tue 31 May 2005

PCRI Insights May, 2005 vol. 8, no. 2 Stephen B. Strum, MD, FACP, Medical Oncologist Specializing in Prostate Cancer and Donna Pogliano, Prostate Cancer Advocate Clinical Practice Prostate Cancer Diagnosis Guidelines Starting at forty years of age, every man should have an annual PSA (prostate-specific antigen) test and a DRE (digital rectal examination). Men atRead More ›

PCRI News – PCRI Produces Educational Lecture in Florida

Mon 9 Feb 2004

Monday, February 9, 2004 In Ft. Myers, Florida, on Saturday, February 7, PCRI staged the first of its planned educational lecture programs. The event proved to be very popular. One hundred and eighty seven people attended the afternoon lecture given by renowned medical oncologist and prostate cancer expert, Dr. Stephen B. Strum. “Lessons From Experience”Read More ›

A Strategy of Success in the Treatment of Prostate Cancer – 3

Wed 31 Jul 2002

PCRI Insights July, 2002 vol. 5, no. 1 By Stephen B. Strum, MD, FACP Page <<  1  2  3 References 1. Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112:138-149, 1940. 2. Steinberg GD, Carter BS, Beaty TH, et al: Family history and the riskRead More ›

A Strategy of Success in the Treatment of Prostate Cancer – 2

Wed 31 Jul 2002

PCRI Insights July, 2002 vol. 5, no. 1 By Stephen B. Strum, MD, FACP Page <<  1  2  3  >> The PSA and PSA Dynamics The absolute values of PSA, the changes in PSA over time, factors associated with PSA increases, and the volume of the prostate gland itself are some of the issues thatRead More ›

Listening to the Biology of Prostate Cancer

Mon 1 Oct 2001

By Stephen B. Strum, M.D. Reprinted from PCRI Insights October 2001 vol. 4, no. 4 Hormonal manipulation plays an important part in the management of prostate cancer at all stages of this disease. The common denominator of these endocrine therapies is the alteration in biologic milieu characterized by androgen deprivation. At the most fundamental level,Read More ›

The Importance of Concordance in Prostate Cancer Management

Sun 1 Oct 2000

Prepared by the PCRI Helpstaff with oversight by Stephen B. Strum, MD Reprinted from PCRI Insights October 2000 vol. 3, no. 3 Concordance is a concept that is pertinent when the cell population of the tumor is not homogeneous but rather is heterogeneous. If the tumor cell population is heterogeneous, it may be more orRead More ›

Important Principles in Chemotherapy: Regimens Treating And Androgen-Independent Prostate Cancer (AIPC)

Wed 1 Dec 1999

By Stephen B. Strum, MD Reprinted from PCRI Insights December 1999, vol. 2, no. 4 One of the greatest problems we face today is how to prevent the emergence of AIPC and how to treat it when it develops. AIPC is defined as disease progression evidenced by a progressively rising PSA (three consecutive rises ofRead More ›

Anemia Associated With Androgen Deprivation (AAAD)

Sat 1 May 1999

by S. B. Strum, J. E. McDermed, M. C. Scholz, H. Johnson and G. Tisman This article originally appeared as a booklet, last edited May, 1999. An Overview And Description Of This Adverse Effect Commonly Seen In Prostate Cancer Patients Receiving Combination Hormone Blockade ABSTRACT Objectives To describe the incidence, time to onset and extentRead More ›